 |
Printer Friendly
Printed from http://www.researchandmarkets.com/reports/350588
The Future of BioSciences: Four Scenarios for 2020 and their Implications for Human Healthcare
|
Description: |
This ground breaking, 132 page report links current information on emerging life sciences technologies with a scenario planning approach to identify growth opportunities and threats between now and 2020.
In the coming years, the convergence of genomics, proteomics, stem cell research, regenerative medicine, bioinformatics, nanotechnology and other life science technologies will pose significant opportunities and challenges in every sector of society. Two years ago, we, along with the William and Phyllis Mack Center for Technological Innovation, part of the Wharton School of the University of Pennsylvania, embarked on an ambitious program to lay out a range of reasonable futures for biosciences. Based on numerous workshops at the Mack Center and individual interviews with over 50 leading experts from academia, government and the private sector, the report represents a truly unique undertaking.
This report presents four scenarios that describe how emerging life science technologies might impact human healthcare between now and 2020. Major trends and uncertainties are identified, as well as key stakeholder groups expected to play a significant role in shaping the future. The Four Scenarios describe the commercialization potential of emerging bioscience technologies within a framework of potential future forces and events.
Decision-makers can use the meta-scenarios articulated in this report as a starting point for crafting their own strategies for proactive and reactive response to the dynamic and competitive biosciences environment. Our long-term goal is to provide decision makers in various industries with strategic insights needed to develop, commercialize and deploy emerging life science technologies.
Decision-makers who will benefit from this report:
- CEO's, General Managers, Executives - Business Unit Leaders - Strategists - Marketing Executives - Investors/Analysts
Industries and other stakeholders:
- Pharmaceuticals - Biotechnology - Healthcare Providers - Advocacy Group - Academic Medical & Biotechnology Programs - Undergraduate & Graduate Business or Strategy Programs
Acquire this Report and begin to visualize the future of your industry...
How Scenarios Can Help Decision Makers Anticipate the Future
What Is Scenario Planning? Scenario planning is a management tool for visualizing and describing several “possible futures” based on trends, uncertainties, stakeholder roles and cause-and- effect relationships (drivers). This approach is especially applicable to technology-driven industries that are evolving under conditions of high uncertainty and complexity.
Scenarios can be “meta-scenarios” that apply to an entire industry or set of technologies (such as biosciences), or “micro-scenarios” for a specific firm, industry or interest group. The scenario planning approach we developed enabled our research team to identify the most important uncertainties in biosciences, and use those to describe likely scenarios that can be monitored and planned for. For the biosciences, we identified “technological success” and “public support” as two critical variables/drivers, and these became the parameters for the 2x2 matrix used to create the four scenarios.
Ideally, decision makers can use these meta-scenarios as a starting-point to craft micro-scenarios and strategies for their organization, industry and environment. Our report identifies the trends, uncertainties and strategic factors that will influence commercialization of life science technologies and the evolution of health care in the coming decades.
Who Can Benefit From Reading This Report?
This report offers value to individuals and organizations in many fields, including: - Managers in pharmaceuticals, biotechnology, insurance, consumer products and other industries who are planning their business strategies, - Policymakers trying to understand how to address the factors that will transform the future, - Healthcare providers and practitioners, and - Consumers and advocacy groups who want safe, effective, affordable medical cures and treatments. |
|
Contents: |
PART I: INTRODUCTION
CHAPTER 1: ASSESSING THE FUTURE OF BIOSCIENCES Defining the Biosciences Space The Scenario Planning Approach
CHAPTER 2: BIOSCIENCES TODAY The Remarkable March of Technology Nanotechnology and Bioinformatics Industry and Technology Convergence The Current Pharma Business Model Developed vs. Developing Markets Promises and Pitfalls
PART II: FOUR SCENARIOS FOR THE FUTURE OF BIOSCIENCES
CHAPTER 3: SCENARIO A – WHERE’S THE BEEF? Scenario A: How We Got Here Themes in Scenario A: The World We Live In Scenario A: How We Live In This World
CHAPTER 4: SCENARIO B – NEW AGE OF MEDICINE Scenario B: How We Got Here Themes in Scenario B: The World We Live In Scenario B: How We Live In This World
CHAPTER 5: SCENARIO C – BIO GRIDLOCK Scenario C: How We Got Here Themes in Scenario C: The World We Live In Scenario C: How We Live In This World
CHAPTER 6: SCENARIO D – SCIENCE HELD HOSTAGE Scenario D: How We Got Here Themes in Scenario D: The World We Live In Scenario D: How We Live In This World
PART III: NEXT STEPS
CHAPTER 7: PROFITING FROM UNCERTAINTY Building a Strategic Framework Lessons for Managing Emerging Technologies Organizational Strategies for Innovation In Conclusion
APPENDICES I. DRIVERS OF CHANGE Long Term Trends Key Uncertainties The Role of Stakeholders
II. SYSTEM DYNAMIC MODELING The Basic Model Simulation Technical Notes and Equations
III. BIBLIOGRAPHY |
|
Summary: |
Four Scenarios for the Future of BioSciences
No one can reliably predict if emerging life science technologies will be wildly successful, or fall short of expectations—or whether the public will accept or reject these new scientific techniques. What we do know for certain is that multiple futures are possible. So how do we describe, anticipate and plan for these possible futures?
Prof. Paul Schoemaker has led a team of management researchers from the Mack Center for Technological Innovation at the Wharton School, and senior consultants from Decision Strategies International (DSI), to develop four scenarios that describe the commercialization potential of emerging bioscience technologies from now until 2020 and beyond
A. WHERE’S THE BEEF? Patients and practitioners want and need medical solutions to treat and cure disease, but science falls far short of expectations.
B. NEW AGE OF MEDICINE Medical science achieves unprecedented breakthroughs that cure disease, help people live longer and ushers in a new age of personalized medicine.
C. BIO GRIDLOCK Genomics, stem cells and other life sciences cause much commotion but fail to achieve their early promise. Research investment dries up and remains stalemated about ethical “what ifs.”
D. SCIENCE HELD HOSTAGE Medicine and healthcare strive to develop and commercialize embryonic stem cells, cloning, gene therapy and other technologies, but the public rejects these technologies at a deep level.
How Decision Makers Can Use These Scenarios
Whether your organization is a pharmaceutical firm, biotech startup, government agency, NGO, or patient advocacy group, you need to think about the long-term future and consider the drivers that will shape the future.
The Future of BioSciences team at the Wharton School has developed four “meta-scenarios” that senior managers and strategic planners can use as a starting-point to create micro-scenarios for specific industries and environments.
In the coming months and years, DSI and the Future of BioSciences team will monitor industry trends, winning and losing strategies, best practices and critical issues. Our goal is to provide insights of interest and value to decision makers in organizations that are developing, deploying or benefiting from bioscience technologies. |
|
Companies Mentioned |
Genentech
Merck
GlaxoSmithKline
Novartis
ImClone
Bristol Myers Squibb
Millennium Pharmaceuticals
Abbott Laboratories
Isis Pharmaceuticals
Eli Lilly
Anadys Pharmaceutical
Pfizer
Sanofi-Aventis
Coley Pharmaceutical Group
IDEC Pharmaceuticals
Biogen
chrion
PowderJect Pharmaceuticals
3M
Reliance Group (India)
Hitachi Chemical Research Center Inc. (Japan/California)
Toumaz Technology
Oracle
Johnson & Johnson
Apovia (USA)
Microsoft
Apple
Unix
IBM
Kodak Company
Procter & Gamble
Siemens
Vanda Pharmaceuticals |
|
Ordering: |
Order Online - visit http://www.researchandmarkets.com/reports/350588
Order by Fax - using the order form below
Order By Post - print the order form below and send to
 |
Research and Markets,
Guinness Centre,
Taylors Lane,
Dublin 8,
Ireland.
|
|
|
 |
Page 1 of 2 Printed 17/02/2012 02:15:50 |
|
Fax Order Form
To place an order via fax simply print this form, fill in the information below and
fax the completed form to
646-607-1907 (from USA) or +353 1 6849977 (from Rest of World). If you have any questions please email help@researchandmarkets.net
Order information
Please verify that the product information is correct and select the format you require.
|
|
|
Product Name: |
The Future of BioSciences: Four Scenarios for 2020 and their Implications for Human Healthcare
|
|
Web Address: |
http://www.researchandmarkets.com/reports/350588
|
|
Office Code: |
|
OC8IHINLSNNSS
|
Report formats
Please enter the quantity of the report format you require.
|
|
Format
|
Quantity
|
Price
|
|
Electronic (PDF)
- Single User
|
|
€2,889.00
|
|
Hard Copy
|
|
€2,996.00 + EUR€ 50.00 Shipping/Handling *
|
* Shipping/Handling is only charged once per order.
Contact information
Please enter all the information below in BLOCK CAPITALS.
 |
|
First Name: |
Last Name: |
|
Email Address: |
 |
|
Job Title: |
 |
|
Organisation: |
 |
|
Address: |
 |
|
City: |
 |
|
Postal/Zip Code: |
 |
|
Country: |
 |
|
Phone Number: |
 |
|
Fax Number: |
 |
|
Please fax this form to: (646) 607-1907 or (646) 964-6609 (from USA) +353-1-481-1716 or +353-1-653-1571 (from Rest of World)
 |
Page 2 of 2 Printed 17/02/2012 02:15:50
|
|
Payment information
Please indicate the payment method you would like to use by selecting the appropriate
box.
|
|
|
|
American Express
|
|
Diners Club
|
|
Master Card
|
|
Visa
|
|
|
|
 |
|
Cardholder's Name: |
 |
|
|
|
Cardholder's Signature: |
 |
|
|
|
Expiry Date: |
/  |
|
|
|
Card Number: |
 |
|
|
|
CVV Security Code: |
 |
|
|
|
Issue Date: |
/ (Diners
Club only)
|
|
|
|
 |
Please post the check, accompanied by this form, to:
Research and Markets,
Guinness Centre,
Taylors Lane,
Dublin 8,
Ireland.
|
|
 |
|
 |
Please transfer funds to:
 |
|
Account number: |
83313083 |
|
Sort code: |
98-53-30 |
|
Swift code: |
ULSBIE2D |
|
IBAN number: |
IE78ULSB98533083313083 |
|
Bank Address: |
Ulster Bank,
27-35 Main St,
Blackrock,
Co. Dublin,
Ireland. |
|
|
|
If you have a Marketing Code please enter it below:
|
|
|
Marketing Code: |
 |
|
Please note that by ordering from Research and Markets you are agreeing to our Terms and Conditions at http://www.researchandmarkets.com/info/terms.asp
|
|
Please fax this form to: (646) 607-1907 or (646) 964-6609 (from USA) +353-1-481-1716 or +353-1-653-1571 (from Rest of World)
|
 |
 |
|
|